MGRM vs. OBIO, RCEL, UTMD, NPCE, DCTH, TLSI, PROF, ARAY, DRTS, and CVRX
Should you be buying Monogram Orthopaedics stock or one of its competitors? The main competitors of Monogram Orthopaedics include Orchestra BioMed (OBIO), AVITA Medical (RCEL), Utah Medical Products (UTMD), NeuroPace (NPCE), Delcath Systems (DCTH), TriSalus Life Sciences (TLSI), Profound Medical (PROF), Accuray (ARAY), Alpha Tau Medical (DRTS), and CVRx (CVRX). These companies are all part of the "surgical & medical instruments" industry.
Monogram Orthopaedics (NASDAQ:MGRM) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, community ranking, valuation and institutional ownership.
0.5% of Monogram Orthopaedics shares are held by institutional investors. Comparatively, 53.6% of Orchestra BioMed shares are held by institutional investors. 32.1% of Monogram Orthopaedics shares are held by insiders. Comparatively, 6.7% of Orchestra BioMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Orchestra BioMed received 6 more outperform votes than Monogram Orthopaedics when rated by MarketBeat users.
In the previous week, Orchestra BioMed had 2 more articles in the media than Monogram Orthopaedics. MarketBeat recorded 3 mentions for Orchestra BioMed and 1 mentions for Monogram Orthopaedics. Orchestra BioMed's average media sentiment score of 1.34 beat Monogram Orthopaedics' score of 0.30 indicating that Orchestra BioMed is being referred to more favorably in the news media.
Orchestra BioMed has a consensus target price of $17.00, suggesting a potential upside of 113.03%. Given Orchestra BioMed's higher probable upside, analysts clearly believe Orchestra BioMed is more favorable than Monogram Orthopaedics.
Monogram Orthopaedics has a net margin of 0.00% compared to Orchestra BioMed's net margin of -2,330.46%. Orchestra BioMed's return on equity of -70.18% beat Monogram Orthopaedics' return on equity.
Monogram Orthopaedics has higher earnings, but lower revenue than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than Monogram Orthopaedics, indicating that it is currently the more affordable of the two stocks.
Summary
Orchestra BioMed beats Monogram Orthopaedics on 9 of the 15 factors compared between the two stocks.
Get Monogram Orthopaedics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGRM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MGRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Monogram Orthopaedics Competitors List
Related Companies and Tools
